Free Trial
NASDAQ:BFRI

Biofrontera Q1 2025 Earnings Report

Biofrontera logo
$0.72 +0.03 (+4.33%)
Closing price 04:00 PM Eastern
Extended Trading
$0.72 0.00 (-0.42%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biofrontera EPS Results

Actual EPS
N/A
Consensus EPS
-$0.14
Beat/Miss
N/A
One Year Ago EPS
N/A

Biofrontera Revenue Results

Actual Revenue
N/A
Expected Revenue
$10.55 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biofrontera Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
10:00AM ET

Conference Call Resources

Biofrontera Earnings Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
See More Biofrontera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biofrontera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biofrontera and other key companies, straight to your email.

About Biofrontera

Biofrontera (NASDAQ:BFRI), a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

View Biofrontera Profile

More Earnings Resources from MarketBeat